In September 2015, we received European Marketing Authorization for Raxone in the treatment of patients with LHON. This makes Raxone (idebenone 150 mg) the first and only medicine approved for this condition. Indeed, it is the first medicine approved for any mitochondrial disorder: a major milestone in addressing the unmet medical need represented by this group of rare diseases.
▼The European Medicines Agency (EMA) has indicated that this medicine is subject to additional monitoring.
Raxone is also being investigated for the treatment of Duchenne muscular dystrophy (DMD) and primary progressive multiple sclerosis (PPMS). In addition, Santhera’s pipeline includes omigapil, an investigational drug with anti-apoptotic properties, a compound in development to address unmet medical needs for patients with congenital muscular dystrophy (CMD).
If you are a healthcare professional, please click below to find out more about our development pipeline:
Access to Raxone varies by the country from which the order is being placed. Bottles containing 180 tablets of Raxone (idebenone 150 mg) are currently available as follows:
European Union Member States, Norway and Iceland
For availability in one of the countries above please contact firstname.lastname@example.org.
For availability in Switzerland please contact Spezialapotheke MediService:
Phone: +41 800 220 222
Fax: +41 32 686 28 05
Albania, Bosnia and Herzegovina, Kosovo, Montenegro, Republic of Macedonia (F.Y.R.O.M.), Serbia
For availability in these countries please contact Clinigen Group:
Phone: +44 1932 824 123
United States and all other countries not included above
For availability in the US and all other countries not included above please contact Masters Speciality Pharma:
Phone: +44 208 327 0900
Fax: +44 208 327 0901